FDA

white pills

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

After Time named President-Elect Donald Trump Person of the Year, calling him President of the Divided States of America, there was one more ebb and flow for the state of business ...
Read Full Story »
FDA_logo

Repros Therapeutics Drops on FDA Vote

Repros Therapeutics Inc. (NASDAQ: RPRX) saw its shares take a loss on Wednesday after the company provided a key U.S. Food and Drug Administration (FDA) update. The company participated in ...
Read Full Story »
FDA_logo

10 Major Pharma and FDA Catalysts Coming in December

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
FDA_logo

PhaseRx More Than Doubles on Key FDA Approval

Shares of PhaseRx Inc. (NASDAQ: PZRX) more than doubled on Monday after the company announced that it received a key U.S. Food and Drug Administration (FDA) approval. The company announced ...
Read Full Story »
burning cash

Amedica Slides on Mixed FDA Updates

Amedica Corp. (NASDAQ: AMDA) is watching its shares drop on Tuesday despite receiving mixed news from the U.S. Food and Drug Administration, along with a new appointment to its management ...
Read Full Story »
FDA_logo

Oragenics Practically Doubles on FDA Decision

Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug ...
Read Full Story »
hammered

4 Companies That Destroyed Shareholders Last Week

Now that the U.S. presidential election is over and markets have recovered to their highs, there are still some stocks holding back the markets from breaking even higher. 24/7 Wall ...
Read Full Story »
research

Aurinia Pharmaceuticals Rises on Positive Mid-Stage Update

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) saw a handy gain on Wednesday after the company gave an update on its lupus nephritis (LN) treatment. Specifically, the company highlighted additional ...
Read Full Story »
fender bender

4 Companies That Destroyed Shareholders Last Week

The U.S. presidential election is now over and markets have seemingly recovered to just below their highs but there are still some laggards. 24/7 Wall Street has picked out a ...
Read Full Story »
Hepatitis Virus

Gilead Scores Another Hepatitis FDA Approval

The biotech industry had enjoyed years of growth, but the past year was tarnished on the political election rhetoric about drug pricing. If one company had been at the center of criticism, ...
Read Full Story »
Hepatitis Virus

Why Arrowhead Pharmaceuticals Shares Are Sliding

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares plummeted early on Wednesday after the company gave an update on its hepatitis B virus (HBV) treatment. Unfortunately, Arrowhead was notified verbally by the ...
Read Full Story »
automatic inspection machine

Why These 2 Biopharma Companies Are Running

A couple of biopharma companies were on the move Monday morning after they announced positive interim results from a late-stage trial. Ionis Pharmaceuticals Inc. (NASDAQ: IONS) announced, in conjunction with ...
Read Full Story »
Doctor Explaining Consent Form To Senior Patient

Aurinia Pharmaceuticals Jumps on Phase 3 Trial Plans

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares saw a handy gain on Thursday morning after the company announced plans for a late-stage trial in the treatment of lupus nephritis. After the company ...
Read Full Story »
Female patient on gurney

Ariad Pharma Rises on FDA Decision

Shares of Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) saw a modest gain early Monday after the company announced a recent U.S. Food and Drug Administration (FDA) decision. Specifically, the FDA said that ...
Read Full Story »
unlike

Why Negative Analyst Views May Matter So Much on Ariad

Shares of Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) were down handily on Monday. The drop follows news that JPMorgan downgraded the stock to Underweight from Neutral. The firm also set a $7 price target. ...
Read Full Story »